WDR5 is a prognostic biomarker of brain metastasis from non-small cell lung cancer

Li, Zheng; Liang, Nan; Wang, Na; Jia, Yan; Tian, Changlin

doi:10.3389/fonc.2022.1023776

Cited by 4 publications

(5 citation statements)

References 40 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probably, an explanation regarding this intolerance with a clinical point of view could help the readers better understandi, such as the detection of related markers during the treatment or when the intolerance symptoms started to become observable. 4,5 Even though the toxicity mentioned here was only shown by two patients in this study, this issue still could also be proposed for a further study. In addition, the typical toxicities, explained as treatment-related adverse events, were listed without detailed information of each point, such as the liver, kidney, and thyroid function.…”

mentioning

confidence: 74%

A Response to Article Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year after Standard Treatment [Letter]

Panjaitan¹

2022

OTT

View full text Add to dashboard Cite

mentioning

confidence: 74%

A Response to Article Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year after Standard Treatment [Letter]

Panjaitan¹

2022

OTT

View full text Add to dashboard Cite

“…Among these proteins, WD repeat-containing protein 5 (WDR5) attracted our attention, which was a key component of histone H3K4 methyltransferase complex, and could catalyze H3K4me3 [ 24 ]. It is well-known that H3K4me3 is associated with the transcriptional activation of target genes [ 25 ]. Moreover, previous study demonstrated that WDR5 served as a tumor-promoter in NB and high level of WDR5 was positively correlated with poor prognosis of NB patients [ 26 ].…”

Section: Resultsmentioning

confidence: 99%

LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN

Yang,

Liu,

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Background Oncogene MYCN is closely related with malignant progression and poor prognosis of neuroblastoma (NB). Recently, long non-coding RNAs (lncRNAs) have been recognized as crucial regulators in various cancers. However, whether lncRNAs contribute to the overexpression of MYCN in NB is unclear. Methods Microarray analysis were applied to analyze the differentially expressed lncRNAs between MYCN-amplified and MYCN-non-amplified NB cell lines. Bioinformatic analyses were utilized to identify lncRNAs nearby MYCN locus. qRT-PCR was used to detect the expression level of lncRNA AC142119.1 in NB cell lines and tissues. Gain- and loss-of-function assays were conducted to investigate the biological effect of AC142119.1 in NB. Fluorescence in situ hybridization, RNA pull-down, RNA immunoprecipitation, mass spectrometry, RNA electrophoretic mobility shift, chromatin immunoprecipitation and chromatin isolation by RNA purification assays were performed to validate the interaction between AC142119.1 and WDR5 protein as well as MYCN promoter. Results AC142119.1 was significantly elevated in NB tissues with MYCN amplification, advanced INSS stage and high risk, and associated with poor survival of NB patients. Moreover, enforced expression of AC142119.1 reinforced the proliferation of NB cells in vitro and in vivo. Additionally, AC142119.1 specifically recruited WDR5 protein to interact with MYCN promoter, further initiating the transcription of MYCN and accelerating NB progression. Conclusions We identified a novel lncRNA AC142119.1, which promoted the progression of NB through epigenetically initiating the transcription of MYCN via interacting with both WDR5 protein and the promoter of MYCN, indicating that AC142119.1 might be a potential diagnostic biomarker and therapeutic target for NB.

show abstract

“…Treatment to patients with BM from NSCLC has not got total consensus ( 25 ). The treatments depend on the performance status, the effect of other adjuvant therapy and overall health of the patient ( 18 ). Many conflicts exist as to the treatment options and the large-scale and multi-centered cohort study should be conducted.…”

Section: Discussionmentioning

confidence: 99%

“…CCKAR expression in NSCLC and BM was detected and semi-qualified with IHC by streptavidin peroxidase complex method as previous described ( 18 ). Slides were treated with boiled citrate buffer (pH = 6.0) for antigen retrieval.…”

Section: Methodsmentioning

confidence: 99%

CCKAR is a biomarker for prognosis and asynchronous brain metastasis of non-small cell lung cancer

Liang¹,

Sun²,

Zheng³

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

BackgroundNon-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, and brain metastasis (BM) is the most lethal complication of NSCLC. The predictive biomarkers and risk factors of asynchronous BM are still unknown.Materials and methodsA total of 203 patients with NSCLC were enrolled into our cohort and followed up. The clinicopathological factors such as tumor size, T stage, lymphatic invasion, metastasis and asynchronous BM were investigated. CCKAR expression in NSCLC and resected BM was assessed by IHC, and CCKAR mRNAs in NSCLC and para-tumor tissues were estimated by qRT-PCR. The correlations between CCKAR expression, BM and other clinicopathological factors were assessed by chi-square test, and prognostic significance of CCKAR was estimated by univariate and multivariate analyses.ResultsCCKAR was highly expressed in NSCLC tissues compared with para-tumor tissues. CCKAR expression in NSCLC was significantly associated with asynchronous BM. The BM percentages for NSCLC patients with low and high CCKAR were surprisingly 5.2% and 66.6%, respectively. CCKAR expression and BM were unfavorable factors predicting unfavorable outcome of NSCLC. Moreover, CCKAR expression in NSCLC was an independent risk factor of asynchronous BM.ConclusionsCCKAR is a prognostic biomarker of NSCLC. CCKAR expression in NSCLC is positively associated with asynchronous BM, and is a risk factor of asynchronous BM from NSCLC.

show abstract

WDR5 is a prognostic biomarker of brain metastasis from non-small cell lung cancer

Cited by 4 publications

References 40 publications

A Response to Article Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year after Standard Treatment [Letter]

A Response to Article Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year after Standard Treatment [Letter]

LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN

CCKAR is a biomarker for prognosis and asynchronous brain metastasis of non-small cell lung cancer

Contact Info

Product

Resources

About